Selected Recent Publications

  • Trimarco JD*, Nelson SL*, Chaparian RR, Wells AI, Murray NB, Azadi P, Coyne CB, Heaton NS. Cellular glycan modification by B3GAT1 broadly restricts influenza virus infection. Nat Commun. 2022 Oct 29;13(1):6456. doi: 10.1038/s41467-022-34111-0. PMID: 36309510; PMCID: PMC9617049. *Contributed  Equally
  • Yaron TM, Heaton BE, Levy TM, Johnson JL, Jordan TX, Cohen BM, Kerelsky A, Lin TY, Liberatore KM, Bulaon DK, Van Nest SJ, Koundouros N, Kastenhuber ER, Mercadante MN, Shobana-Ganesh K, He L, Schwartz RE, Chen S, Weinstein H, Elemento O, Piskounova E, Nilsson-Payant BE, Lee G, Trimarco JD, Burke KN, Hamele CE, Chaparian RR, Harding AT, Tata A, Zhu X, Tata PR, Smith CM, Possemato AP, Tkachev SL, Hornbeck PV, Beausoleil SA, Anand SK, Aguet F, Getz G, Davidson AD, Heesom K, Kavanagh-Williamson M, Matthews DA, tenOever BR, Cantley LC, Blenis J, Heaton NS. Host protein kinases required for SARS-CoV-2 nucleocapsid phosphorylation and viral replication. Sci Signal. 2022 Oct 25;15(757):eabm0808. doi: 10.1126/scisignal.abm0808. Epub 2022 Oct 25. PMID: 36282911.
  • Zhu X, Trimarco JD, Williams CA, Barrera A, Reddy TE, Heaton NS. ZBTB7A promotes virus-host homeostasis during human coronavirus 229E infection. Cell Rep. 2022 Oct 25;41(4):111540. doi: 10.1016/j.celrep.2022.111540. Epub 2022 Oct 5. PMID: 36243002; PMCID: PMC9533670.
  • Hamele CE, Russell AB, Heaton NS. In Vivo Profiling of Individual Multiciliated Cells during Acute Influenza A Virus Infection. J Virol. 2022 Jul 27;96(14):e0050522. doi: 10.1128/jvi.00505-22. Epub 2022 Jul 6. PMID: 35867557; PMCID: PMC9327675.
  • Chaparian RR, Harding AT, Hamele CE, Riebe K, Karlsson A, Sempowski GD, Heaton NS*, Heaton BE*. A Virion-Based Combination Vaccine Protects against Influenza and SARS-CoV-2 Disease in Mice. J Virol. 2022 Jul 12:e0068922. doi: 10.1128/jvi.00689-22. Epub ahead of print. PMID: 35862698. *Co-corresponding
  • Froggatt HM, Burke KN, Chaparian RR, Miranda HA, Zhu X, Chambers BS, Heaton NS. Influenza A virus segments five and six can harbor artificial introns allowing expanded coding capacity. PLoS Pathog. 2021 Sep 27;17(9):e1009951. doi: 10.1371/journal.ppat.1009951. PMID: 34570829; PMCID: PMC8496794.
  • Drayman N, DeMarco JK, Jones KA, Azizi SA, Froggatt HM, Tan K, Maltseva NI, Chen S, Nicolaescu V, Dvorkin S, Furlong K, Kathayat RS, Firpo MR, Mastrodomenico V, Bruce EA, Schmidt MM, Jedrzejczak R, Muñoz-Alía MÁ, Schuster B, Nair V, Han KY, O’Brien A, Tomatsidou A, Meyer B, Vignuzzi M, Missiakas D, Botten JW, Brooke CB, Lee H, Baker SC, Mounce BC, Heaton NS, Severson WE, Palmer KE, Dickinson BC, Joachimiak A, Randall G, Tay S. Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2. Science. 2021 Jul 20:eabg5827. doi: 10.1126/science.abg5827. PMID: 34285133.
  • Froggatt HM, Harding AT, Chaparian RR, Heaton NS. ETV7 limits antiviral gene expression and control of influenza viruses. Science Signaling. 2021 Jul 13;14(691):eabe1194. doi: 10.1126/scisignal.abe1194. PMID: 34257104.
  • Trimarco JD, Heaton BE, Chaparian RR, Burke KN, Binder RA, Gray GC, Smith CM, Menachery VD, Heaton NS. TMEM41B is a host factor required for the replication of diverse coronaviruses including SARS-CoV-2. PLoS Pathog. 2021 May 27;17(5):e1009599. doi: 10.1371/journal.ppat.1009599. PMID: 34043740; PMCID: PMC8189496.
  • Luo Z, Girton AW, Heaton BE, Heaton NS. Engineered influenza virions reveal the contributions of non-hemagglutinin structural proteins to vaccine mediated protection. J Virol. 2021 Mar 3;95(10):e02021-20. doi: 10.1128/JVI.02021-20. Epub ahead of print. PMID: 33658342; PMCID: PMC8139674.
  • Harding AT, Goff MA, Froggatt HM, Lim JK, Heaton NS. GPER1 is required to protect fetal health from maternal inflammation. Science. 15 January, 2021: Vol. 371, Issue 6526, pp. 271-276. DOI: 10.1126/science.aba9001
  • Katsura H, Sontake V, Tata A, Kobayashi Y, Edwards CE, Heaton BE, Konkimalla A, Asakura T, Mikami Y, Fritch EJ, Lee PJ, Heaton NS, Boucher RC, Randell SH, Baric RS, Tata PR. Human Lung Stem Cell-Based Alveolospheres Provide Insights into SARS-CoV-2-Mediated Interferon Responses and Pneumocyte Dysfunction. Cell Stem Cell. 2020 Oct 21:S1934-5909(20)30499-9. doi: 10.1016/j.stem.2020.10.005.
  • Dumm RE, Wellford SA, Moseman EA*, Heaton NS*.  Heterogeneity of Antiviral Responses in the Upper Respiratory Tract Mediates Differential Non-lytic Clearance of Influenza Viruses.  Cell Reports. 32:9. 108103 Sept 1, 2020. *Co-corresponding
  • Froggatt HM, Heaton BE, Heaton NS. Development of a fluorescence based, high-throughput SARS-CoV-2 3CLproreporter assay. Journal of Virology. August, 2020. doi:1128/JVI.01265-20
  • Abbott TR, Dhamdhere G, Liu Y, Lin X, Goudy L, Zeng L, Chemparathy A, Chmura S, Heaton NS, Debs R, Pande T, Endy D, La Russa MF, Lewis DB, Qi LS. Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza. Cell. 2020 Apr 29. pii: S0092-8674(20)30483-9. https://doi.org/10.1016/j.cell.2020.04.020
  • Harding AT, Haas GD, Chambers BC, Heaton NS. Influenza viruses that required 10 genomic segments as antiviral therapeutics. PLoS Pathogens. 2019. Nov 15;15(11):e1008098. doi: 10.1371/journal.ppat.1008098. PMID: 31730644
  • Fiege JK, Stone IA, Dumm RE, Waring BM, Fife BT, Agudo J, Brown B, Heaton NS, Langlois RA. Long-term surviving influenza infected cells evade CD8+ T cell mediated clearance. PLoS Pathogens. 2019 Sep 26;15(9):e1008077. doi: 10.1371/journal.ppat.1008077. PMID: 31557273
  • Dumm RE and Heaton NS. The Development and Use of Reporter Influenza B Viruses. Viruses. 2019, 11(8), 736; https://doi.org/10.3390/v11080736
  • Chambers BS, Heaton BE, Rausch K, Dumm RE, Hamilton JR, Cherry S*, Heaton NS*. DNA mismatch repair is required for the host innate response and control cellular fate after influenza virus infection. Nature Microbiology. 2019. Nov;4(11):1964-1977. *Co-corresponding
  • Dumm RE, Fiege JK, Waring BM, Kuo CT, Langlois RA, Heaton NS. Non-lytic clearance of influenza B virus from infected cells preserves epithelial barrier function. Nature Communications. 2019 Feb 15;10(1):779. doi: 10.1038/s41467-019-08617-z. PMID: 30770807
  • Harding AT, Heaton NS. Efforts to Improve the Seasonal Influenza Vaccine. Vaccines.  2018 March 30;6(2). pii: E19. doi: 10.3390/vaccines6020019. PMID:29601497
  • Heaton BE, Kennedy EM, Dumm RE, Harding AT, Sacco MT, Sachs D, Heaton NS. A CRISPR Activation Screen Identifies a Pan-avian Influenza Virus Inhibitory Host Factor. Cell Reports. 2017 20(7): p1503-1512. http://dx.doi.org/10.1016/j.celrep.2017.07.060 PMID: 28813663
  • Heaton NS. Revisiting the concept of a cytopathic viral infection. PLoS Pathogens. 2017 13(7): e1006409. https://doi.org/10.1371/journal.ppat.1006409 PMID: 28727844
  • Harding AT, Heaton BE, Dumm RE, Heaton NS. Rationally Designed Influenza Virus Vaccines That Are Antigenically Stable during Growth in Eggs. mBio. 2017 June 6, Vol. 8 no.3 e00669-17 doi: 10.1128/mBio.00669-17 PMID: 28588131
  • Hamilton JR, Sachs D, Lim JK, Langlois RA, Palese P, Heaton NS. Club cells surviving influenza A virus infection induce temporary non-specific anti-viral immunity. Proc Natl. Acad Sci USA. 2016 April 5, vol. 113 no. 14, 3861-3866. doi: 10.1073/pnas.1522376113. PMID: 27001854
  • Fulton BO, Palese P, Heaton NS. Replication competent influenza B reporter viruses as tools for screening antivirals and antibodies. Journal of Virology. 2015 Dec 1;89(23):12226-31. doi: 10.1128/JVI.02164-15. Epub 2015 Sep 23. PMID:26401044
  • Fulton BO, Sachs D, Beaty SM, Won ST, Lee B, Palese P, Heaton NS. Mutational analysis of measles virus suggests constraints on antigenic variation of the glycoproteins. Cell Reports. 2015 Jun 9;11(9):1331-8. doi: 10.1016/j.celrep.2015.04.054. Epub 2015 May 21. PMID:26004185

A complete list of published work from Dr. Heaton is available here